Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New combo attack on recurrent head & neck cancer: immunotherapy plus radiation before surgery

NCT ID NCT04754321

First seen Nov 01, 2025 · Last updated May 01, 2026 · Updated 23 times

Summary

This early-phase trial is for people with head and neck cancer that has persisted or returned after prior treatment. It tests whether giving the immunotherapy drug pembrolizumab along with radiation before and during surgery can help kill more cancer cells. The main goals are to understand the side effects of this combination and to see how well it controls the cancer. About 45 adults whose tumors can be surgically removed will take part.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEAD AND NECK CARCINOMA OF UNKNOWN PRIMARY are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Ohio State University Comprehensive Cancer Center

    RECRUITING

    Columbus, Ohio, 43210, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

Conditions

Explore the condition pages connected to this study.